SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No.2)
Meridian Medical Technologies, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $.10 par value
--------------------------------------------------------------------------------
(Title of Class of Securities)
589658103
--------------------------------------------------------------------------------
(CUSIP Number)
Robert G. Foster, 4 Milk Street, Portland, ME 04101 (207) 780-0904
--------------------------------------------------------------------------------
(Name, Address, Telephone Number of Persons Authorized to Receive Notices and
Communications)
April 1, 2002
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
Page 1 of Pages
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON
Commonwealth BioVentures V Limited Partnership
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
Not Applicable
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS [ ]
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
--------------------------------------------------------------------------------
NUMBER OF SHARES 7 SOLE VOTING POWER
BENEFICIALLY OWNED BY EACH
REPORTING PERSON WITH 0
------------------------------------------------
8 SHARED VOTING POWER
36,297
------------------------------------------------
9 SOLE DISPOSITIVE POWER
0
------------------------------------------------
10 SHARED DISPOSITIVE POWER
36,297
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
36,297
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.83%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
PN
--------------------------------------------------------------------------------
Schedule 13D Commonwealth BioVentures V Limited Partnership
ITEM 2. IDENTITY AND BACKGROUND
The reporting person's name is Commonwealth BioVentures V Limited
Partnership, a Delaware limited partnership. The reporting person's principal
business is that of a venture capital fund. The general partner of the reporting
person is BioVenture Partners Limited Partnership, a Delaware limited
partnership ("BVLP"). The general partner of BVLP is Commonwealth BioVentures,
Inc., a Massachusetts corporation ("CBI"). The President and principal
stockholder of CBI is Robert Foster, a U.S. citizen. The business address for
each of the entities and the individual identified above is 4 Milk Street,
Portland, ME 04101.
During the last five years, none of the entities or the individual
identified in the paragraph above have been (i) convicted in a criminal
proceeding (excluding traffic violations and similar misdemeanors) or (ii) a
party to a civil proceeding of a judicial or administrative body of competent
jurisdiction and as a result of such proceeding has been or is subject to a
judgment, decree or final order enjoining future violations of, or prohibiting
or mandating activities subject to, federal or state securities laws or finding
any violation with respect to such laws.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
The number of shares of the Issuer's common stock that the reporting person
may be deemed to beneficially own is 36,297 (the "Shares"), representing
approximately 0.83% of the reported outstanding shares of the Issuer's common
stock as of February 28, 2002. By virtue of the relationships described in Item
2 above among the reporting person, BVLP, CBI and Mr. Foster, the reporting
person shares the power to vote and the power to dispose of the Shares with each
of those persons. The reporting person ceased to be a beneficial owner of more
than 5% of the Issuer's common stock between November 30, 2001 and February 28,
2002 as a result of a reported increase in the aggregate number of outstanding
shares of the Issuer's common stock between those two dates.
The reporting person, a venture fund, is in its last year of existence and
has commenced liquidating fund investments in contemplation of the reporting
person's termination and winding up of its business. On April 1, 2002, the
reporting person distributed to its limited partners an aggregate of 150,000
shares of the Issuer's common stock registered in the reporting person's name in
accordance with the terms of the reporting person's limited partnership
agreement (the "Distribution"). The Distribution was effected solely as part of
the reporting person's investment liquidation process and was not influenced by
or otherwise based upon the reporting person's evaluation of the Issuer's
current or anticipated business, financial, or stock price performance.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete, and
correct.
COMMONWEALTH BIOVENTURES
V LIMITED PARTNERSHIP
By: Bioventure Partners Limited
Partnership, its general partner
By: Commonwealth BioVentures, Inc., its
general partner
April 2, 2002 By: /s/ Robert G. Foster
------------- ----------------------------
Robert G. Foster, President